Loading...
Loading...
Healthcare
Executive compensation benchmarks for 13 public companies in the biological products, (no diagnostic substances) industry.
$12.7M
13
$24.4M
40:1
Median
$12,741,421
Average
$14,541,754
25th Percentile
$10,002,498
75th Percentile
$19,876,180
Minimum
$5,965,903
Maximum
$24,428,495
Avg Pay Ratio
40:1
Companies
13
Click any company to see full compensation breakdown
The median biological products, (no diagnostic substances) CEO compensation is $12,741,421, based on 13 public companies. The average is $14,541,754. Note that CEO compensation includes salary, bonus, stock awards, option awards, and other compensation.
Robert A. Bradway of AMGEN INC is the highest paid biological products, (no diagnostic substances) CEO, with total compensation of $24,428,495 in FY2024.
The average CEO-to-median-employee pay ratio in the biological products, (no diagnostic substances) industry is 40:1. This means the average CEO earns 40 times what the median employee earns.
Data sourced from SEC filings (DEF 14A proxy statements). Last updated: March 1, 2026. Compensation figures are total annual compensation including salary, bonus, stock awards, and other compensation.
Compare CEO compensation across different industries or research specific companies.
| Company | CEO | Total Comp |
|---|---|---|
| AMGEN INC AMGN | Robert A. Bradway | $24.4M |
| GILEAD SCIENCES, INC. GILD | Daniel P. O’Day | $23.7M |
| REPLIGEN CORP RGEN | Tony J. Hunt | $20.3M |
| Moderna, Inc. MRNA | Stéphane Bancel | $19.9M |
| Vaxcyte, Inc. PCVX | Grant E. Pickering | $16.9M |
| Krystal Biotech, Inc. KRYS | Krish S. Krishnan | $15.6M |
| HALOZYME THERAPEUTICS, INC. HALO | Helen I. Torley | $12.7M |
| EXELIXIS, INC. EXEL | Michael M. Morrissey | $12.7M |
| Revolution Medicines, Inc. RVMD | Mark A. Goldsmith | $10.1M |
| BIOGEN INC. BIIB | C. Viehbacher | $10.0M |
| NEUROCRINE BIOSCIENCES INC NBIX | Kyle W. Gano | $8.5M |
| BIO-TECHNE Corp TECH | Kim Kelderman | $8.2M |
| Cidara Therapeutics, Inc. CDTX | Jeffrey Stein | $6.0M |